Atlas Trials

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

Clinical trial NCT07311746 · RECRUITING

Trial details

NCT number
NCT07311746
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
T-cell Prolymphocytic LeukemiaRefractory T-Cell Prolymphocytic Leukemia
Start date
2026-04-28
Primary completion
2029-01-31
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.